Artelo Biosciences, Inc. (ARTL)
ARTL moved a median of 0.00% 30 minutes after news, and -0.23% by the close. How ARTL actually reacts to news — the realized, point-in-time move the market made, measured across 239 labeled events over the last three years with zero look-ahead.
ARTL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 25% | 219 |
| 30-min | 0.00% | 41% | 237 |
| 60-min | 0.00% | 47% | 238 |
| to close | -0.23% | 44% | 237 |
| Middle 50% of ARTL reactions | -2.15% to +1.23% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 239 |
Half of all Artelo Biosciences, Inc. news events land between -2.15% and +1.23% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ARTL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ARTL's baseline. Nothing else.
Recent ARTL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K ARTELO BIOSCIENCES, INC. For: Oct 09 | SEC filing · Form 8-K | SEC EDGAR | -0.31% | -2.81% | |
| Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform | Press release | GlobeNewswire | -1.47% | +0.29% | |
| Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings | Press release | GlobeNewswire | -1.74% | +81.84% | |
| Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity | Press release | GlobeNewswire | -5.71% | -23.47% | |
| Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | — | +2.48% | |
| Artelo Biosciences Announces Reverse Stock Split | Press release | GlobeNewswire | -1.45% | -3.50% | |
| Form 8-K ARTELO BIOSCIENCES, INC. For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | -1.45% | -3.50% | |
| Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 | Press release | GlobeNewswire | -0.76% | -0.43% | |
| Form 10-Q/A ARTELO BIOSCIENCES, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.31% | -3.89% | |
| Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies | Press release | GlobeNewswire | +0.00% | -6.36% | |
| Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results | Press release | GlobeNewswire | +3.91% | +5.14% | |
| Form 10-Q ARTELO BIOSCIENCES, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.91% | +5.14% | |
| Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma | Press release | GlobeNewswire | -2.07% | — | |
| New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition | Press release | GlobeNewswire | -2.72% | -1.83% | |
| Form 8-K ARTELO BIOSCIENCES, INC. For: Jul 17 | SEC filing · Form 8-K | SEC EDGAR | -1.72% | -3.45% | |
| Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions | Press release | GlobeNewswire | -2.65% | +0.89% | |
| Form DEFA14A ARTELO BIOSCIENCES, INC. | SEC filing · Form DEFA14A | SEC EDGAR | -2.65% | +0.89% | |
| Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026 | Press release | GlobeNewswire | -3.74% | +8.41% | |
| Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy | Press release | GlobeNewswire | -2.88% | +0.96% | |
| Form DEFA14A ARTELO BIOSCIENCES, INC. | SEC filing · Form DEFA14A | SEC EDGAR | -0.91% | -1.80% | |
| Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury | Press release | GlobeNewswire | -5.26% | -3.51% | |
| Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 | Press release | GlobeNewswire | +0.93% | +3.70% | |
| Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 | Press release | GlobeNewswire | -0.10% | -3.51% | |
| Form PRER14A ARTELO BIOSCIENCES, INC. | SEC filing · Form PRER14A | SEC EDGAR | +0.00% | +2.44% | |
| Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success | Press release | GlobeNewswire | -0.77% | +0.00% | |
| Form ARS ARTELO BIOSCIENCES, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.49% | -0.75% | |
| Form DEF 14A ARTELO BIOSCIENCES, INC. For: Jul 17 | SEC filing · Form DEF | SEC EDGAR | +1.49% | -0.75% | |
| Form DEFA14A ARTELO BIOSCIENCES, INC. | SEC filing · Form DEFA14A | SEC EDGAR | +1.49% | -0.75% | |
| Form 8-K ARTELO BIOSCIENCES, INC. For: May 26 | SEC filing · Form 8-K | SEC EDGAR | +4.72% | +14.96% | |
| Form PRE 14A ARTELO BIOSCIENCES, INC. For: Jul 17 | SEC filing · Form PRE | SEC EDGAR | -4.82% | +0.74% | |
| Form EFFECT ARTELO BIOSCIENCES, INC. | SEC filing · Form EFFECT | SEC EDGAR | -6.01% | +6.77% | |
| Form 8-K ARTELO BIOSCIENCES, INC. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -12.94% | -14.12% | |
| Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results | Press release | GlobeNewswire | +1.56% | -17.86% | |
| Form 10-Q ARTELO BIOSCIENCES, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.56% | -17.86% | |
| Form S-3/A ARTELO BIOSCIENCES, INC. | SEC filing · Form S-3 | SEC EDGAR | +1.56% | -17.86% | |
| Form S-3 ARTELO BIOSCIENCES, INC. | SEC filing · Form S-3 | SEC EDGAR | -1.86% | -4.64% | |
| Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development | Press release | GlobeNewswire | -1.08% | -3.77% | |
| Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile | Press release | GlobeNewswire | +2.16% | -11.79% | |
| Form EFFECT ARTELO BIOSCIENCES, INC. | SEC filing · Form EFFECT | SEC EDGAR | -0.39% | -4.71% | |
| Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements | Press release | GlobeNewswire | -1.68% | +6.81% | |
| Form 8-K ARTELO BIOSCIENCES, INC. For: Apr 06 | SEC filing · Form 8-K | SEC EDGAR | -0.14% | +5.35% | |
| Form S-1 ARTELO BIOSCIENCES, INC. | SEC filing · Form S-1 | SEC EDGAR | +2.21% | +0.59% | |
| Form D ARTELO BIOSCIENCES, INC. | SEC filing · Form D | SEC EDGAR | — | -1.12% | |
| Form EFFECT ARTELO BIOSCIENCES, INC. | SEC filing · Form EFFECT | SEC EDGAR | -0.11% | -25.10% | |
| Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | Press release | GlobeNewswire | -0.11% | -25.10% | |
| Form 8-K ARTELO BIOSCIENCES, INC. For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | -0.11% | -25.10% | |
| Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | Press release | GlobeNewswire | -6.86% | +6.25% | |
| Form D ARTELO BIOSCIENCES, INC. | SEC filing · Form D | SEC EDGAR | -0.70% | +12.64% | |
| Form RW ARTELO BIOSCIENCES, INC. | SEC filing · Form RW | SEC EDGAR | +7.28% | +32.25% | |
| Form 8-K ARTELO BIOSCIENCES, INC. For: Mar 20 | SEC filing · Form 8-K | SEC EDGAR | +7.28% | +32.25% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ARTL section they belong to.
Where else ARTL is measured.
ARTL earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MARIMED INC (MRMD) | 240 | +0.28% | 54% |
| Resverlogix Corp (RVX_TSE) | 240 | 0.00% | 32% |
| Lixte Biotechnology Holdings, Inc. (LIXT) | 239 | 0.00% | 48% |
| MeiraGTx Holdings plc - Ordinary Shares (MGTX) | 239 | -0.10% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Artelo Biosciences, Inc.'s median reaction calculated?
Every labeled ARTL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 239 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of ARTL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ARTL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.